In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example

Bishnu P. De, Alvin Chen, Christiana O. Salami, Benjamin Van De Graaf, Jonathan B. Rosenberg, Odelya E. Pagovich, Dolan Sondhi, Ronald Crystal, Stephen M. Kaminsky

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The development of a drug product requires rigorous methods of characterization and quality control to assure drug potency. Gene therapy products, a relatively new strategy for drug design with very few licensed examples, represent a unique challenge for the measure of potency. Unlike traditional drugs, potency for a gene therapeutic is a tally of the measures of multiple steps, including infectivity, transcription, translation, protein modifications, proper localization of the protein product, and protein function. This is particularly challenging for products based on the adeno-associated virus (AAV) platform, which has poor in vitro infectivity, limiting the sensitivity and thus the usefulness of cell-based assays. A rigorous in vivo assay has been established that separately evaluates infection, transcription, and resulting protein levels with specifications for each based on real time polymerase chain reaction (DNA and RNA) and standard protein assays. For an acceptance criterion, an administered vector must have vector DNA, transgene mRNA, and transgene expressed protein each concurrently meet individual specifications or the production lot fails. Using the AAVrh.10 serotype as a model vector and three different transgenes as examples, the assay is based on intravenous administration of the vector to male mice. At 2 weeks, the harvested liver is homogenized and assessed for vector genome levels (to assess for vector delivery), mRNA (to assess vector infectivity and transcription), and protein in the liver or serum (to assess protein expression). For all AAV vectors, the assay is robust and reproducible: vector DNA (linearity 102-109 copies, coefficient of variation) intra-assay <0.8%, inter-assay <0.5%; mRNA intra-assay <3.3%, inter-assay <3.4%. The reproducibility of the assay for transgene expressed protein is product specific. This in vivo potency assay is a strategy for characterization and a quantitative lot release test, providing a path forward to meet regulatory drug requirements for any AAV gene therapy vectors.

Original languageEnglish
Pages (from-to)146-155
Number of pages10
JournalHuman gene therapy methods
Volume29
Issue number3
DOIs
Publication statusPublished - 1 Jun 2018

Fingerprint

Dependovirus
Genetic Therapy
Transgenes
Proteins
Pharmaceutical Preparations
Messenger RNA
DNA
Drug Design
Liver
Protein Biosynthesis
Quality Control
Intravenous Administration
Real-Time Polymerase Chain Reaction
Genome
RNA
Infection
Serum

Keywords

  • AAV Vectors
  • Gene therapy
  • potency
  • quality control

ASJC Scopus subject areas

  • Molecular Medicine
  • Applied Microbiology and Biotechnology
  • Genetics
  • Pharmacology
  • Genetics(clinical)

Cite this

De, B. P., Chen, A., Salami, C. O., Van De Graaf, B., Rosenberg, J. B., Pagovich, O. E., ... Kaminsky, S. M. (2018). In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example. Human gene therapy methods, 29(3), 146-155. https://doi.org/10.1089/hgtb.2017.246

In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example. / De, Bishnu P.; Chen, Alvin; Salami, Christiana O.; Van De Graaf, Benjamin; Rosenberg, Jonathan B.; Pagovich, Odelya E.; Sondhi, Dolan; Crystal, Ronald; Kaminsky, Stephen M.

In: Human gene therapy methods, Vol. 29, No. 3, 01.06.2018, p. 146-155.

Research output: Contribution to journalArticle

De, BP, Chen, A, Salami, CO, Van De Graaf, B, Rosenberg, JB, Pagovich, OE, Sondhi, D, Crystal, R & Kaminsky, SM 2018, 'In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example', Human gene therapy methods, vol. 29, no. 3, pp. 146-155. https://doi.org/10.1089/hgtb.2017.246
De, Bishnu P. ; Chen, Alvin ; Salami, Christiana O. ; Van De Graaf, Benjamin ; Rosenberg, Jonathan B. ; Pagovich, Odelya E. ; Sondhi, Dolan ; Crystal, Ronald ; Kaminsky, Stephen M. / In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example. In: Human gene therapy methods. 2018 ; Vol. 29, No. 3. pp. 146-155.
@article{448356f9731945d2af2f74e552f6c539,
title = "In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example",
abstract = "The development of a drug product requires rigorous methods of characterization and quality control to assure drug potency. Gene therapy products, a relatively new strategy for drug design with very few licensed examples, represent a unique challenge for the measure of potency. Unlike traditional drugs, potency for a gene therapeutic is a tally of the measures of multiple steps, including infectivity, transcription, translation, protein modifications, proper localization of the protein product, and protein function. This is particularly challenging for products based on the adeno-associated virus (AAV) platform, which has poor in vitro infectivity, limiting the sensitivity and thus the usefulness of cell-based assays. A rigorous in vivo assay has been established that separately evaluates infection, transcription, and resulting protein levels with specifications for each based on real time polymerase chain reaction (DNA and RNA) and standard protein assays. For an acceptance criterion, an administered vector must have vector DNA, transgene mRNA, and transgene expressed protein each concurrently meet individual specifications or the production lot fails. Using the AAVrh.10 serotype as a model vector and three different transgenes as examples, the assay is based on intravenous administration of the vector to male mice. At 2 weeks, the harvested liver is homogenized and assessed for vector genome levels (to assess for vector delivery), mRNA (to assess vector infectivity and transcription), and protein in the liver or serum (to assess protein expression). For all AAV vectors, the assay is robust and reproducible: vector DNA (linearity 102-109 copies, coefficient of variation) intra-assay <0.8{\%}, inter-assay <0.5{\%}; mRNA intra-assay <3.3{\%}, inter-assay <3.4{\%}. The reproducibility of the assay for transgene expressed protein is product specific. This in vivo potency assay is a strategy for characterization and a quantitative lot release test, providing a path forward to meet regulatory drug requirements for any AAV gene therapy vectors.",
keywords = "AAV Vectors, Gene therapy, potency, quality control",
author = "De, {Bishnu P.} and Alvin Chen and Salami, {Christiana O.} and {Van De Graaf}, Benjamin and Rosenberg, {Jonathan B.} and Pagovich, {Odelya E.} and Dolan Sondhi and Ronald Crystal and Kaminsky, {Stephen M.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1089/hgtb.2017.246",
language = "English",
volume = "29",
pages = "146--155",
journal = "Human gene therapy methods",
issn = "1946-6536",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example

AU - De, Bishnu P.

AU - Chen, Alvin

AU - Salami, Christiana O.

AU - Van De Graaf, Benjamin

AU - Rosenberg, Jonathan B.

AU - Pagovich, Odelya E.

AU - Sondhi, Dolan

AU - Crystal, Ronald

AU - Kaminsky, Stephen M.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The development of a drug product requires rigorous methods of characterization and quality control to assure drug potency. Gene therapy products, a relatively new strategy for drug design with very few licensed examples, represent a unique challenge for the measure of potency. Unlike traditional drugs, potency for a gene therapeutic is a tally of the measures of multiple steps, including infectivity, transcription, translation, protein modifications, proper localization of the protein product, and protein function. This is particularly challenging for products based on the adeno-associated virus (AAV) platform, which has poor in vitro infectivity, limiting the sensitivity and thus the usefulness of cell-based assays. A rigorous in vivo assay has been established that separately evaluates infection, transcription, and resulting protein levels with specifications for each based on real time polymerase chain reaction (DNA and RNA) and standard protein assays. For an acceptance criterion, an administered vector must have vector DNA, transgene mRNA, and transgene expressed protein each concurrently meet individual specifications or the production lot fails. Using the AAVrh.10 serotype as a model vector and three different transgenes as examples, the assay is based on intravenous administration of the vector to male mice. At 2 weeks, the harvested liver is homogenized and assessed for vector genome levels (to assess for vector delivery), mRNA (to assess vector infectivity and transcription), and protein in the liver or serum (to assess protein expression). For all AAV vectors, the assay is robust and reproducible: vector DNA (linearity 102-109 copies, coefficient of variation) intra-assay <0.8%, inter-assay <0.5%; mRNA intra-assay <3.3%, inter-assay <3.4%. The reproducibility of the assay for transgene expressed protein is product specific. This in vivo potency assay is a strategy for characterization and a quantitative lot release test, providing a path forward to meet regulatory drug requirements for any AAV gene therapy vectors.

AB - The development of a drug product requires rigorous methods of characterization and quality control to assure drug potency. Gene therapy products, a relatively new strategy for drug design with very few licensed examples, represent a unique challenge for the measure of potency. Unlike traditional drugs, potency for a gene therapeutic is a tally of the measures of multiple steps, including infectivity, transcription, translation, protein modifications, proper localization of the protein product, and protein function. This is particularly challenging for products based on the adeno-associated virus (AAV) platform, which has poor in vitro infectivity, limiting the sensitivity and thus the usefulness of cell-based assays. A rigorous in vivo assay has been established that separately evaluates infection, transcription, and resulting protein levels with specifications for each based on real time polymerase chain reaction (DNA and RNA) and standard protein assays. For an acceptance criterion, an administered vector must have vector DNA, transgene mRNA, and transgene expressed protein each concurrently meet individual specifications or the production lot fails. Using the AAVrh.10 serotype as a model vector and three different transgenes as examples, the assay is based on intravenous administration of the vector to male mice. At 2 weeks, the harvested liver is homogenized and assessed for vector genome levels (to assess for vector delivery), mRNA (to assess vector infectivity and transcription), and protein in the liver or serum (to assess protein expression). For all AAV vectors, the assay is robust and reproducible: vector DNA (linearity 102-109 copies, coefficient of variation) intra-assay <0.8%, inter-assay <0.5%; mRNA intra-assay <3.3%, inter-assay <3.4%. The reproducibility of the assay for transgene expressed protein is product specific. This in vivo potency assay is a strategy for characterization and a quantitative lot release test, providing a path forward to meet regulatory drug requirements for any AAV gene therapy vectors.

KW - AAV Vectors

KW - Gene therapy

KW - potency

KW - quality control

UR - http://www.scopus.com/inward/record.url?scp=85048932212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048932212&partnerID=8YFLogxK

U2 - 10.1089/hgtb.2017.246

DO - 10.1089/hgtb.2017.246

M3 - Article

VL - 29

SP - 146

EP - 155

JO - Human gene therapy methods

JF - Human gene therapy methods

SN - 1946-6536

IS - 3

ER -